Page 81 - BH-3-3
P. 81

Brain & Heart                                                             Updates on the treatment of PFO



            based decisions, yet the precision of treatment selection   Availability of data
            remains limited in individual cases if only strict criteria are
            used. High numbers-needed-to-treat in some “high-risk”   Not applicable.
            groups  suggest  unnecessary  interventions,  while  broad   Further disclosure
            confidence intervals in “low-risk” groups indicate potential
            undertreatment due to rigid criteria.              Part of work has been presented in the “Heart, Brain and
                                                               Vessels” meeting held in Aosta on June 13–14, 2024.
              As emphasized in guidance papers, clinical judgment
            should always complement formal criteria, considering   References
            factors beyond current classifications. For instance, on
            the  one  hand,  PFO  closure  might  be  appropriate  in  a   1.   Pristipino C, Sievert H, D’Ascenzo F,  et  al. European
                                                                  position paper on the management of patients with patent
            young PFO-associated cryptogenic stroke patient despite   foramen ovale. General approach and left circulation
            an “unlikely” PASCAL classification if the stroke clearly   thromboembolism. Eur Heart J. 2019;40(38):3182-3195.
            coincided with a pulmonary embolism. On the other
            hand, in elderly people, the complexity of comorbidities      doi: 10.1093/eurheartj/ehy649
            in real life may render possible positive results of ongoing   2.   Wein  T,  Lindsay  MP,  Côté  R,  et al.  Canadian  stroke  best
            randomized studies problematic to generalize.         practice recommendations: Secondary prevention of stroke,
                                                                  sixth edition practice guidelines, update 2017. Int J Stroke.
              Scientifically, the simultaneous high prevalence of PFO   2018;13(4):420-443.
            and a rare causal impact highlight the possible shortcomings
            of classic statistics and the need for complexity-based      doi: 10.1177/1747493017743062
            approaches. Deterministic models may no longer suffice;   3.   Messé SR, Gronseth GS, Kent DM, et al. Practice advisory
            instead, multiparametric phenotyping and big data     update summary: Patent foramen ovale and secondary
            tools offer promise for refining patient selection. These   stroke prevention: Report of the guideline subcommittee
            challenges exemplify broader issues in medicine, where   of the American academy of neurology.  Neurology.
            PFO management could lead the way in developing       2020;94(20):876-885.
            precision treatments. The convergence of technology and      doi: 10.1212/WNL.0000000000009443
            data science signals a transformative era in individualized   4.   Kleindorfer DO, Towfighi A, Chaturvedi S,  et  al. 2021
            care, while attempting to address a single cause of disease   Guideline for the prevention of stroke in patients with
            may be unrealistic in complex scenarios such as in the   stroke and transient ischemic attack: A guideline from the
            increasing elderly population where simultaneous multiple   American heart association/American stroke association.
            forms of prevention may be required at the individual level.  Stroke. 2021;52(7):e364-e467.
            Acknowledgments                                       doi: 10.1161/STR.0000000000000375

            None.                                              5.   Kavinsky  CJ,  Szerlip  M,  Goldsweig  AM,  et al. SCAI
                                                                  Guidelines for the management of patent foramen ovale.
            Funding                                               J Soc Cardiovasc Angiogr Interv. 2022;1(4):100039.
                                                                  doi: 10.1016/j.jscai.2022.100039
            None.
                                                               6.   Caso V, Turc G, Abdul‑Rahim AH, et al. European stroke
            Conflict of interest                                  organisation (ESO) guidelines on the diagnosis and
                                                                  management of patent foramen ovale (PFO) after stroke.
            The authors declare they have no competing interests.
                                                                  Eur Stroke J. 2024;9(4):800-834.
            Author contributions                                  doi: 10.1177/23969873241247978
            Conceptualization: All authors                     7.   Kent  DM,  Saver  JL,  Kasner  SE,  et al. Heterogeneity of
            Writing–original draft: All authors                   treatment effects in an analysis of pooled individual patient
            Writing–review & editing: All authors                 data from randomized trials of device closure of patent
                                                                  foramen ovale after stroke. JAMA. 2021;326(22):2277-2286.
            Ethic approval and consent to participate             doi: 10.1001/jama.2021.20956
            Not applicable.                                    8.   Pristipino  C,  Carroll  J,  Mas  JL,  Wunderlich  NC,
                                                                  Sondergaard  L. Treatment of patent foramen ovale.
            Consent for publication                               Eurointervention. 2025;21(10):505-524.
            Not applicable.                                       doi: 10.4244/EIJ‑D‑23‑00915


            Volume 3 Issue 3 (2025)                         6                                doi: 10.36922/bh.8133
   76   77   78   79   80   81   82   83   84   85   86